Clinical trial imaging refers to the use of medical imaging technologies — MRI, CT, PET, ultrasound, and others — to collect standardized, quantifiable data within a research study. Rather than imaging a patient to guide individual treatment, clinical trial imaging generates evidence: it measures disease at baseline, tracks how participants respond to an intervention, and produces the imaging endpoints that support regulatory decisions.
Clinical trial imaging is the structured use of imaging modalities within a research protocol to answer specific scientific questions about a disease, a treatment, or a diagnostic technology. According to the National Cancer Institute's Cancer Imaging Program:
"An imaging clinical trial is a research study conducted with people who volunteer to take part. Each study answers specific scientific questions."
In clinical practice, imaging serves individual patients — a radiologist reads a scan to guide a diagnosis or treatment decision. In clinical trials, the purpose is different: imaging produces standardized, reproducible data across all participants and sites so that results can be compared, pooled, and submitted to regulators as evidence. This distinction shapes everything from how protocols are written to how images are acquired, reviewed, and archived.
Imaging trials span several types:
Imaging plays a more demanding role in clinical trials than in routine clinical care. As Lars Johansson, Chief Scientific Officer at Antaros Medical, explains:
"In clinical practice, imaging is used primarily by healthcare professionals for diagnosis and follow-up of disease progression/regression... In clinical trials for drug development, imaging serves to quantify treatment effect in a standardised way that allows for comparisons."
That distinction has direct consequences for how imaging data must be handled. In a trial, imaging data is evidence for a regulatory submission. It must be reproducible across sites, defensible under audit, and captured at the right time points with sufficient quality to support the study's primary endpoints. When imaging data is poor — inconsistent acquisition, missing time points, unresolved quality issues — it does not just create operational problems. It undermines the scientific validity of the trial.
In oncology, this is especially visible. As noted in research published in PMC: "Imaging techniques are increasingly used in oncological clinical trials to provide evidence for decision making." The same applies across neurology, cardiovascular, and musculoskeletal research where imaging endpoints are central to drug approval pathways.
Medical imaging in clinical trials is not a single activity — it runs through the entire study, from screening to final data lock. Understanding where imaging touches the trial helps explain why workflow standardization matters so much. Here is how each use case works in practice, and what happens when it is not managed carefully.
Before a participant can be enrolled in many trials, imaging is used to confirm they meet the eligibility criteria defined in the protocol. In an oncology trial, a baseline CT or MRI might confirm measurable lesion size or location. In a neurology trial, imaging might confirm the presence of a specific biomarker — amyloid plaques in Alzheimer's research, for example. Getting screening imaging right matters: a participant enrolled on the basis of a non-qualifying scan wastes resources, introduces variability, and can compromise the study's statistical foundation. Sites need clear instructions on acquisition parameters before the first participant is screened.
Baseline imaging establishes the reference point against which all subsequent scans are compared. It must be acquired within the protocol-specified window before treatment begins — sometimes within a matter of days. A late or incomplete baseline creates a missing anchor that makes it impossible to measure response accurately at later time points. The baseline scan also documents the participant's disease state at enrollment, providing essential context for both efficacy assessment and safety monitoring if findings change unexpectedly during the trial.
At each subsequent time point, imaging tracks whether the intervention is producing a measurable effect. In oncology, criteria like RECIST define exactly how to measure tumor response from sequential scans. In other therapeutic areas, imaging might measure plaque reduction, joint space narrowing, or organ perfusion. Each scan must be acquired under the same protocol conditions as the baseline — any deviation in acquisition parameters introduces variability that is difficult to account for in the analysis and can make response assessments unreliable.
Imaging biomarkers are quantifiable features in medical images — tumor volume, bone density, lesion count, perfusion measurements — that can serve as primary or secondary endpoints in a trial. The FDA increasingly accepts imaging endpoints as surrogate endpoints for drug approval, which can significantly shorten trial timelines by providing early biological evidence of effect. For an imaging biomarker to be accepted, it must be validated, consistently measured across sites, and assessed in a blinded, standardized way that holds up to regulatory scrutiny. This requires careful protocol design and a workflow that enforces measurement consistency.
Imaging contributes to safety monitoring when an intervention carries potential for toxicity or structural changes that would be visible on a scan. Cardiac imaging is standard in trials involving cardiotoxic agents. Brain MRI is required in many CNS trials to detect unexpected findings before they become serious adverse events. Safety imaging follows the same protocol discipline as efficacy imaging — missed time points and non-compliant acquisitions can leave safety signals undetected and create liability for sponsors and CROs managing the data.
Centralized review — where images are assessed by independent, blinded readers — is a regulatory requirement for many primary imaging endpoints. It removes the variability introduced by site-level reads and provides the objective, auditable assessment that regulators expect. Blinded independent central review (BICR) requires a structured workflow: images are routed to qualified readers in a defined order, measurements and determinations are captured in an auditable format, and disagreements between primary readers go through formal adjudication. Platforms built for ICTMS support this end-to-end, including time-point locking, blinding enforcement, and read package assembly for regulatory submission.
Most imaging trials run across multiple sites in multiple countries, each with different scanners, software versions, and local practices. Managing this complexity requires centralized data collection, standardized protocols enforced at every site, and quality oversight that catches deviations early. As noted in a multicenter guide for clinical research by Collective Minds, success in these studies depends on standardized imaging parameters, secure data handling, and regular equipment calibration across all participating sites. Without centralized oversight, variability accumulates site by site until it becomes a problem that cannot be corrected at lock.
Imaging trials offer significant advantages for medical research:
According to Medpace: "Imaging technologies, such as MRI and ultrasound, come with a number of advantages, including non-invasiveness and the potential for early outcome detection."
Despite their value, imaging trials face real operational challenges:
Managing the data generated across imaging-heavy trials requires more than general-purpose software. Imaging Clinical Trial Management Systems (ICTMS) are purpose-built platforms that centralize image storage, automate workflow steps, and enforce the quality controls that multi-site trials require.
A well-implemented ICTMS provides:
Teams that implement a purpose-built platform early — rather than adapting general-purpose tools — spend less time managing exceptions and more time on the science.
A growing development in the field is the emergence of virtual imaging trials (VITs), which use computer simulations to evaluate imaging technologies without requiring human subjects. According to the Radiological Society of North America, VITs are used "to evaluate and optimize the design and clinical use of medical imaging devices and methods." They reduce cost and time, eliminate radiation risk to participants, and enable researchers to test across a wider range of anatomical variations than physical trials typically allow. As AI becomes more integrated into imaging workflows, virtual trials will play a growing role in validating algorithm performance before clinical deployment.
Clinical trial imaging is not just a data collection activity — it is one of the primary sources of evidence that determines whether a drug works, whether a participant is eligible, and whether the trial can withstand regulatory review. Every step in the imaging workflow, from screening through final read, contributes to or detracts from that evidence.
Teams that treat imaging as an operational afterthought tend to encounter the same problems: non-compliant scans at sites, query backlogs, missing time points, and last-minute data reconciliation at lock. Teams that build imaging workflow discipline into the study from the start — using standardized protocols, a centralized platform, and active quality oversight — produce cleaner data with fewer surprises.
If you are evaluating options for managing choosing right vendor for clinical trials imaging operations, the infrastructure matters as much as the science.
Imaging data in a clinical trial is typically managed by an imaging core lab or the CRO's imaging team, working with a centralized platform. The imaging core lab oversees protocol compliance, quality control, central review, and data delivery to the sponsor. Sites collect images according to the protocol but do not manage the data centrally — that responsibility sits with the team running the imaging operations.
An imaging core lab is a specialized organization that manages the imaging component of a clinical trial independently from the sites and the sponsor. It receives images from all participating sites, performs quality control, organizes central reads by independent blinded reviewers, and delivers imaging data to the sponsor in a format ready for analysis and regulatory submission. Core labs provide the standardization and independence that regulators require for imaging endpoints. For a detailed overview, see imaging core labs in clinical trials.
The main challenges are volume, variability, and compliance. Multi-site trials produce large quantities of DICOM files across different scanner types and software versions. Sites follow protocols imperfectly, generating non-compliant images that require queries and re-submission. De-identification must be applied consistently to every file. And every action — receipt, QC, query, read, determination — must be timestamped and auditable. Without a platform built for this complexity, imaging data management becomes a bottleneck.
Blinded independent central review (BICR) is the process by which qualified readers assess imaging data without knowledge of treatment assignment or site identity. It is a regulatory requirement for many primary imaging endpoints because it removes the bias that can affect site-level reads. BICR workflows include randomization of reads, time-point locking to prevent future scans from influencing earlier assessments, and formal adjudication when primary readers disagree. The result is an objective, auditable imaging assessment that regulators can rely on as evidence.
Reviewed by: Pilar Flores Gastellu on May 12, 2026